Acoustically responsive polydopamine nanodroplets: A novel theranostic agent.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Acoustic Physics

Background:

• Ultrasound-induced cavitation enhances drug delivery but requires high acoustic intensities.
• Current clinical systems face challenges in achieving safe and effective cavitation thresholds.
• Cavitation nuclei, like microbubbles and nanodroplets, can lower required acoustic intensities.

Purpose of the Study:

• To develop and characterize novel polydopamine (PDA)-stabilized nanodroplets as ultrasound-triggered cavitation nuclei.
• To assess the biocompatibility and acoustic properties of these nanodroplets for clinical applications.
• To demonstrate the potential of PDA nanodroplets for enhanced drug delivery and treatment monitoring.

Main Methods:

• Formulation of sub-micrometer (~400 nm) phase-transition nanodroplets stabilized with polydopamine.
• Evaluation of acoustic intensities required to initiate inertial cavitation using clinical ultrasound systems.
• Assessment of nanodroplet biocompatibility through cell viability and haemolysis studies.

Main Results:

• PDA nanodroplets were successfully synthesized and stabilized.
• The acoustic intensities needed for inertial cavitation were achievable with standard clinical ultrasound systems.
• Cell viability and haemolysis studies confirmed the biocompatibility of the PDA nanodroplets.

Conclusions:

• PDA nanodroplets represent a novel, acoustically active nanodevice for biomedical applications.
• These nanodroplets can be fabricated easily, are biocompatible, and functionalizable.
• The technology holds significant potential for improving ultrasound-mediated drug delivery and treatment monitoring.